Oncolytics Biotech logo

Oncolytics BiotechNASDAQ: ONCY

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

05 October 2001

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$90.68 M
-57%vs. 3y high
42%vs. sector
-vs. 3y high
-vs. sector
-46%vs. 3y high
88%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:34:20 GMT
$1.18-$0.02(-1.68%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ONCY Latest News

ONCY Stock Up on Regulatory Update From Breast Cancer Program
zacks.com07 October 2024 Sentiment: POSITIVE

Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a breast cancer indication.

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
prnewswire.com04 October 2024 Sentiment: POSITIVE

Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal cancer clinical trials expected in 2025, with potential for new registration-enabling studies SAN DIEGO and CALGARY, AB , Oct. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is issuing a corporate update to provide investors with a deeper understanding of recent data and what is expected for 2025.  "We're excited by the recent BRACELET-1 results, which exceeded our expectations and substantiate the strong efficacy signal previously observed in breast cancer patients treated with pelareorep," said Wayne Pisano, Interim CEO and Chair of Oncolytics' Board of Directors.

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
prnewswire.com19 September 2024 Sentiment: POSITIVE

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorep-based therapy in advanced or metastatic breast cancer Over half of BRACELET-1 patients in the pelareorep + chemotherapy arm alive at study end Median OS in the pelareorep + chemotherapy arm not reached; median OS at least 32 months (estimated) vs 18 months for the control chemotherapy-only arm SAN DIEGO and CALGARY, AB , Sept. 19, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+/HER2- advanced or metastatic breast cancer.

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September
prnewswire.com06 September 2024 Sentiment: POSITIVE

SAN DIEGO and CALGARY, AB , Sept. 6, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Financial Officer Kirk Look will participate in a fireside chat at the H.C.

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference
prnewswire.com02 August 2024 Sentiment: POSITIVE

SAN DIEGO and CALGARY, AB , Aug. 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Medical Officer Dr. Thomas Heineman will participate in a fireside chat at Canaccord Genuity's 44th Annual Growth Conference, which is taking place August 13-15, 2024 at the InterContinental Boston Hotel in Boston, MA. Additional details on the fireside chat can be found below.

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights
prnewswire.com01 August 2024 Sentiment: POSITIVE

Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024 Dosed first patient in new GOBLET study pancreatic cancer cohort; supported by funding from PanCAN Entered into collaboration with GCAR for inclusion of pelareorep in adaptive registration-enabling pancreatic cancer trial Cash position of $24.9 million provides runway through key milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , Aug. 1, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced recent operational highlights and financial results for the second quarter ended June 30, 2024.

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
prnewswire.com24 June 2024 Sentiment: NEGATIVE

Wayne Pisano, Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer SAN DIEGO and CALGARY, AB , June 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics' Board of Directors, will serve as the interim CEO during Dr. Coffey's absence.

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
prnewswire.com20 June 2024 Sentiment: POSITIVE

Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million Therapeutic Accelerator Award from PanCAN SAN DIEGO, and CALGARY, AB , June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The co-primary endpoints of the cohort are objective response rate (ORR) and safety.

Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
zacks.com04 June 2024 Sentiment: POSITIVE

Oncolytics Biotech (ONCY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
prnewswire.com24 May 2024 Sentiment: POSITIVE

Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indications SAN DIEGO and CALGARY, AB , May 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients.

What type of business is Oncolytics Biotech?

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

What sector is Oncolytics Biotech in?

Oncolytics Biotech is in the Healthcare sector

What industry is Oncolytics Biotech in?

Oncolytics Biotech is in the Biotechnology industry

What country is Oncolytics Biotech from?

Oncolytics Biotech is headquartered in Canada

When did Oncolytics Biotech go public?

Oncolytics Biotech initial public offering (IPO) was on 05 October 2001

What is Oncolytics Biotech website?

https://www.oncolyticsbiotech.com

Is Oncolytics Biotech in the S&P 500?

No, Oncolytics Biotech is not included in the S&P 500 index

Is Oncolytics Biotech in the NASDAQ 100?

No, Oncolytics Biotech is not included in the NASDAQ 100 index

Is Oncolytics Biotech in the Dow Jones?

No, Oncolytics Biotech is not included in the Dow Jones index

When was Oncolytics Biotech the previous earnings report?

No data

When does Oncolytics Biotech earnings report?

The next expected earnings date for Oncolytics Biotech is 08 November 2024